{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:33:30Z","timestamp":1787956410671,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s41669-018-0100-5","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T05:40:02Z","timestamp":1539582002000},"page":"237-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States"],"prefix":"10.1007","volume":"3","author":[{"given":"Jill A.","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Galaznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlo","family":"Blazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai-Che","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Farrelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustina","family":"Ogbonnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Eaddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas V.","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"issue":"S1","key":"100_CR1","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.clml.2016.02.019","volume":"16","author":"RS Komrokji","year":"2016","unstructured":"Komrokji RS. Current state of the art: management of higher risk myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2016;16(S1):S39\u201343.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"100_CR2","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s11899-015-0269-y","volume":"10","author":"CR Cogle","year":"2015","unstructured":"Cogle CR. Incidence and burden of the myelodysplastic syndromes. Curr Hematol Malig Rep. 2015;10(3):272\u201381.","journal-title":"Curr Hematol Malig Rep."},{"issue":"12","key":"100_CR3","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454\u201365.","journal-title":"Blood"},{"key":"100_CR4","unstructured":"National Comprehensive Cancer Network. Myelodysplastic syndromes. V.1.2018. Fort Washington. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf\n                    \n                  . Accessed 4 October 2017."},{"issue":"7","key":"100_CR5","first-page":"455","volume":"5","author":"A Powers","year":"2012","unstructured":"Powers A, Faria C, Broder MS, et al. Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care. Am Health Drug Benefits. 2012;5(7):455\u201365.","journal-title":"Am Health Drug Benefits."},{"issue":"11","key":"100_CR6","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.leukres.2012.07.020","volume":"36","author":"R Wang","year":"2012","unstructured":"Wang R, Gross CP, Frick K, et al. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leuk Res. 2012;36(11):1370\u20135.","journal-title":"Leuk Res"},{"issue":"10","key":"100_CR7","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1111\/j.1537-2995.2012.03626.x","volume":"52","author":"SL Goldberg","year":"2012","unstructured":"Goldberg SL, Chen E, Sasane M, et al. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need. Transfusion. 2012;52(10):2131\u20138.","journal-title":"Transfusion."},{"issue":"5","key":"100_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3109\/10428194.2013.820286","volume":"55","author":"BD Smith","year":"2014","unstructured":"Smith BD, Mahmoud D, Dacosta-Byfield S, Rosen VM. Health care utilization and risk of infection and bleeding among patients with myelodysplastic syndromes with\/without transfusions, and with\/without active therapy. Leuk Lymphoma. 2014;55(5):1119\u201325.","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"100_CR9","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.clinthera.2010.12.003","volume":"32","author":"F Pan","year":"2010","unstructured":"Pan F, Peng S, Fleurence R, et al. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective. Clin Ther. 2010;32(14):2444\u201356.","journal-title":"Clin Ther"},{"issue":"1","key":"100_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3111\/13696998.2011.631067","volume":"15","author":"R Gidwani","year":"2012","unstructured":"Gidwani R, Khan ZM, Fenaux P, et al. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes. J Med Econ. 2012;15(1):145\u201354.","journal-title":"J Med Econ."},{"key":"100_CR11","unstructured":"Bureau of Labor Statistics. CPI Inflation Calculator. 2018. \n                    https:\/\/www.bls.gov\/data\/inflation_calculator.htm\n                    \n                  . Accessed 9 Jul 2018."},{"issue":"3","key":"100_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332.","journal-title":"Lancet Oncol."},{"issue":"8","key":"100_CR13","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794\u2013803.","journal-title":"Cancer"},{"issue":"15","key":"100_CR14","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M L\u00fcbbert","year":"2011","unstructured":"L\u00fcbbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987\u201396.","journal-title":"J Clin Oncol"},{"issue":"6","key":"100_CR15","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1185\/03007995.2015.1031732","volume":"31","author":"SR Arikian","year":"2015","unstructured":"Arikian SR, Milentijevic D, Binder G, et al. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin. 2015;31(6):1105\u201315.","journal-title":"Curr Med Res Opin"},{"key":"100_CR16","doi-asserted-by":"publisher","first-page":"942","DOI":"10.6004\/jnccn.2008.0072","volume":"6","author":"PL Greenberg","year":"2008","unstructured":"Greenberg PL, Cosler LE, Ferro SA, Lyman GH. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw. 2008;6:942\u201353.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"100_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000445163","volume":"136","author":"S Harnan","year":"2016","unstructured":"Harnan S, Ren S, Gomersall T, et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis. Acta Haematol. 2016;136(1):23\u201342.","journal-title":"Acta Haematol"},{"issue":"8","key":"100_CR18","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1185\/03007990903076699","volume":"25","author":"JR Frytak","year":"2009","unstructured":"Frytak JR, Henk HJ, De Castro CM, et al. Estimation of economic costs associated with transfusion dependence in adults with MDS. Curr Med Res Opin. 2009;25(8):1941\u201351.","journal-title":"Curr Med Res Opin"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-018-0100-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41669-018-0100-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-018-0100-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T19:10:41Z","timestamp":1571080241000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41669-018-0100-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["100"],"URL":"https:\/\/doi.org\/10.1007\/s41669-018-0100-5","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]},"assertion":[{"value":"15 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Funding for the research study and resultant publication was provided by Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AG, JB, DF, and RF are employees of Takeda. HS, EF, MB, AO, and ME are employees of Xcenda, which has received research funding from Takeda for the conduct of this study and for the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}